Ajanta Pharma has said the US health regulator has successfully completed inspection of its Dahej facility.
“Company’s formulation facility at Dahej was inspected by United States Food and Drug Administration (USFDA) from April 3 to 7, 2017,” Ajanta Pharma said in a filing to the BSE today.
At the end of the inspection, no Form 483 was issued to the company, it added.
Form 483 is issued to a company’s management after completion of inspection of its facility to notify regarding objectionable conditions.
Shares of Ajanta Pharma were trading 1.24 per cent up at at Rs 1,741 apiece on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.